文献速递肝肾功能剂量调整特殊人群用药治疗药物监测与药物基因组学

连续静脉-静脉血液透析对急性早幼粒细胞白血病合并急性肾损伤患者砷剂疗效与药代动力学的影响

Effect of continuous venovenous haemodialysis on outcome and pharmacokinetics of arsenic species in a patient with acute promyelocytic leukaemia and acute kidney injury.
PubMed 文献 · Br J Clin Pharmacol · 2019-02-14

本文报告1例急性早幼粒细胞白血病合并急性肾损伤患者在接受连续静脉-静脉血液透析(CVVHD)期间使用三氧化二砷(ATO)的结局与药代动力学。血浆与透析液中砷代谢物用高效液相色谱-氢化物发生-原子荧光光谱法分析,CVVHD期间血浆AsIII、单甲基胂酸和二甲基胂酸浓度低于无CVVHD时;患者达完全缓解且肾功能恢复,提示ATO在不调整剂量下可安全有效用于CVVHD患者。

要点

  • CVVHD期间血浆AsIII、单甲基胂酸和二甲基胂酸浓度低于无CVVHD时。
  • 本例患者达完全缓解且肾功能恢复,ATO未调整剂量。

核心结论

  • 在本例急性早幼粒细胞白血病合并急性肾损伤患者中,ATO在不调整剂量下可安全有效地用于接受CVVHD者。

研究设计与样本

  • 研究纳入3例因急性肾损伤接受CVVHD的急性早幼粒细胞白血病患者,最终仅1例纳入分析。
  • 该患者在诱导治疗前出现弥散性血管内凝血和急性肾损伤,接受CVVHD并启动ATO治疗。
  • 用高效液相色谱-氢化物发生-原子荧光光谱法分析血浆和透析液中ATO代谢物种类。

主要发现

  • CVVHD期间血浆AsIII、单甲基胂酸和二甲基胂酸浓度低于无CVVHD时。
  • 单甲基胂酸和二甲基胂酸的AUC0-last在CVVHD与无CVVHD间未见显著差异。
  • 砷代谢物的透析液饱和度显著,尤其对AsIII。
  • 患者达完全缓解且肾功能恢复。

临床怎么用

  • 急性早幼粒细胞白血病合并急性肾损伤需CVVHD者,可考虑使用ATO而不调整剂量。
  • CVVHD期间应关注砷代谢物血浆浓度下降及透析液饱和度,尤其AsIII。

局限性

  • 研究仅纳入1例患者,结果的外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This study presents outcome and pharmacokinetics of arsenic trioxide (ATO) metabolites in patients on continuous venovenous haemodialysis (CVVHD). Of 3 acute promyelocytic leukaemia patients receiving CVVHD in management of acute kidney injury, only 1 patient was included. The patient presented disseminated intravascular coagulation and acute kidney injury before induction therapy was conducted. CVVHD was performed and ATO was initiated. Species of ATO metabolites in plasma and effluent were analysed using high performance liquid chromatography-hydride generation-atomic fluorescence spectrometry. Plasma concentrations of AsIII , monomethylarsonic acid and dimethylarsinic acid with CVVHD were lower than those without CVVHD. Area under the concentration-time curve from 0 to the last sample with quantifiable concentration of AsIII without CVVHD was significantly higher than that with CVVHD (292.10 ng h/mL vs 195.86 ng h/mL, P = .037), which were not observed for monomethylarsonic acid and dimethylarsinic acid. Dialysate saturation of arsenic species was remarkable, especially for AsIII . Complete remission was achieved and renal function recovered. In this study, ATO can be used safely and effectively to treat acute promyelocytic leukaemia patients undergoing CVVHD without dose adjustment.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Gao C, Fan S, Hostetter TH, et al. Effect of continuous venovenous haemodialysis on outcome and pharmacokinetics of arsenic species in a patient with acute promyelocytic leukaemia and acute kidney injury. Br J Clin Pharmacol. 2019. PMID: 30677159. doi:10.1111/bcp.13875

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。